| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Vivos Therapeutics, Inc.$0.5
-0.01 (-2.19%)
Market Cap
8.48 M
EPS
-2.31
P/E Ratio
-
Value Trade
95.56 K
SEC Financials
Q1 2026Dilution Risk
Revenue
5.14 M
Operating CF
-6.01 M
Total Assets
25.04 M
Total Liabilities
26.31 M
Equity
-1.14 M
D/E Ratio
12,345
-11.59 %
Week
-41.9 %
1 Month
-62.8 %
3 Month
-71.5 %
6 Month
-99.57 %
5 Year
-99.65 %
All Time
Cash Data
Cash Position
2.11 M
Monthly Burn
2.00 M
Runway
0.1 mo
Burn Trend
SEC Filing
May 20, 2026
Overview
Volume
500.61 K
52 Week Range
0.55 - 7.95
% held by Insiders
26.22 %
% held by Institutions
13.12 %
Enterprise Value
18.50 M
Total Shares
13.61 M
Short %
7.33 %
Float Shares
10.73 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VVOS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
VVOS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VVOS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VVOS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VVOS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
VVOS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VVOSVivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
Vivos Therapeutics plans to file a registration statement for a proposed rights offering, aiming to distribute subscription rights to shareholders. The offering is contingent on SEC approval, with rights expected to be exercisable for nine months. Management highlights the potential for additional capital to support operations, though uncertainties remain regarding completion.
Read more →VVOSVivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
Vivos Therapeutics has entered a collaboration with South Palm Cardiovascular Associates to form AIM Florida, aimed at improving diagnosis and treatment for patients with obstructive sleep apnea and insomnia who also suffer from cardiovascular disease. This partnership seeks to enhance patient care and expand access to integrated services in Florida. Vivos anticipates that this model could be replicated across the country, although there are uncertainties regarding the finalization of agreements and operational execution.
Read more →VVOSVivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
Vivos Therapeutics will participate in The Small Cap Showcase & WTR Insights on June 9, 2026, in New York City. CEO Kirk Hunstman is set to deliver a corporate presentation and engage in one-on-one meetings with investors. This event aims to highlight investment opportunities among micro and small-cap companies.
Read more →VVOSVivos Therapeutics Reports Full Year 2025 Financial Results
Vivos Therapeutics reported a 16% revenue increase for the full year 2025, driven by a strategic shift towards integrating sleep specialty providers. Despite an operating loss from investments in this new model, management remains optimistic about achieving cash flow positivity by year-end. The company continues to innovate in the treatment of obstructive sleep apnea.
Read more →VVOSVivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
Vivos Therapeutics has achieved in-network status with several commercial health insurers and Medicare in Nevada, enhancing access to its OSA treatments for patients. This development is expected to significantly boost patient volume and revenue. Additionally, Vivos is implementing cost reduction measures aimed at saving $4 million annually, which will help reduce its cash burn rate. The company anticipates that these changes will support its goal of becoming cash flow positive in 2026.
Read more →VVOSRecent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
Vivos Therapeutics announced a study confirming the link between dental morphology and obstructive sleep apnea (OSA) severity. The study, involving 100 participants, showed that specific craniofacial features correlate with OSA, supporting Vivos' treatment approach. Vivos CARE devices, cleared by the FDA, have successfully treated many patients, reducing reliance on traditional therapies like CPAP.
Read more →VVOSVivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies
Vivos Therapeutics has partnered with SoundHealth to distribute innovative allergy and sleep health technologies. This collaboration will utilize Vivos' extensive network of trained providers to enhance public access to SoundHealth's FDA-cleared products, including the Sonu Band and Spatial Sleep band. Both devices aim to improve airway health and sleep quality through advanced technology.
Read more →VVOSVivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
Vivos Therapeutics has successfully closed the exercise of warrants, generating approximately $4.64 million in gross proceeds. The company issued new unregistered warrants in a private placement to facilitate this process. The funds will be utilized for working capital and corporate purposes, as Vivos continues to focus on innovative solutions for obstructive sleep apnea.
Read more →VVOSVivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds
Vivos Therapeutics has announced the exercise of warrants, generating approximately $4.64 million in gross proceeds. The company will issue new unregistered warrants as part of this transaction, which is expected to close around January 20, 2026. The funds will be used for working capital and general corporate purposes, supporting Vivos' ongoing efforts in treating sleep-related disorders.
Read more →VVOSVivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST
Vivos Therapeutics will participate in an online fireside chat on December 16, 2025, featuring CEO Kirk Huntsman and CFO Brad Amman. They will discuss the company's strategic business model, market opportunities, and financial strategies. The event aims to engage investors and highlight Vivos' innovative approaches to treating sleep-related breathing disorders.
Read more →VVOSVivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025
Vivos Therapeutics reported a significant 78% sequential revenue growth in Q3 2025, attributed to the successful integration of the Sleep Center of Nevada. The company is optimistic about future growth as it expands its operations and services in response to increasing patient demand. Management is actively pursuing additional market opportunities and optimizing existing operations.
Read more →VVOSVivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call
Vivos Therapeutics, Inc. plans to release its third quarter 2025 financial results and conduct a conference call on November 19, 2025. The call will cover operational updates and strategic collaborations that may impact revenue growth. Vivos specializes in innovative treatments for sleep-related breathing disorders, including obstructive sleep apnea.
Read more →VVOSVivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
Vivos Therapeutics has released new clinical data demonstrating that its FDA-cleared Daytime-Nighttime Appliance (DNA) significantly improves symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children suffering from obstructive sleep apnea (OSA). The study showed a notable reduction in ADHD symptoms and sleep-disordered breathing, suggesting a promising non-surgical treatment alternative. The findings indicate that addressing OSA may lead to better behavioral outcomes in affected children.
Read more →VVOSVivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
Vivos Therapeutics has announced positive results from a multicenter clinical trial demonstrating the safety and efficacy of its Vivos DNA appliance for treating pediatric obstructive sleep apnea (OSA). The findings, published in the European Journal of Pediatrics, suggest a promising non-surgical alternative to the invasive adenotonsillectomy. This breakthrough could significantly impact the treatment landscape for the estimated 10 million U.S. children affected by OSA.
Read more →VVOSVivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Vivos Therapeutics reported strong second-quarter results, highlighted by the acquisition of The Sleep Center of Nevada, which has generated significant revenue and patient demand for its OSA treatments. The company is pivoting its business model to enhance direct patient relationships and is exploring further acquisitions. Despite some challenges with capacity and legacy revenue, management remains optimistic about future growth.
Read more →VVOSVivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
Vivos Therapeutics, Inc. plans to release its second quarter 2025 financial results on August 19, 2025, followed by a conference call to discuss the results and recent developments. The company specializes in treatments for sleep-related breathing disorders, including obstructive sleep apnea. Vivos' innovative solutions aim to address a significant global health issue, although they face integration and regulatory challenges.
Read more →VVOSVivos Therapeutics Adds to Management Team to Support Expansion and Growth
Vivos Therapeutics has appointed Michael Bruhn as Executive VP of Business Operations Integration and Dr. Terry Jones as Senior VP of Human Resources to support its growth and expansion efforts. These appointments are part of Vivos' strategy to enhance its operations and integrate new acquisitions, including the recent acquisition of The Sleep Center of Nevada. Both leaders bring extensive experience to help Vivos tackle the challenges of obstructive sleep apnea treatment.
Read more →VVOSVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance
Vivos Therapeutics has received Medicare approval for its VidaSleep™ oral appliance, designed for treating mild to moderate obstructive sleep apnea (OSA). This approval is expected to increase accessibility for millions of Medicare beneficiaries and encourages private insurers to follow suit. The VidaSleep™ device, along with the mmRNA® appliance, positions Vivos uniquely in the sleep therapy market, addressing the needs of a significant patient population.
Read more →VVOSVivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
Vivos Therapeutics has successfully acquired The Sleep Center of Nevada, expanding its reach in the obstructive sleep apnea (OSA) market. This acquisition aligns with Vivos' strategic pivot towards high patient volume centers, enhancing revenue potential. The company secured over $11 million in financing to support this transition and aims to integrate SCN's operations to provide effective OSA treatments directly to patients.
Read more →Competitive Position
How VVOS ranks across every disease it competes inCompetitive Position is a premium feature
See how VVOS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial